Report Detail
Global Cardiovascular Drug Market Insights, Forecast to 2025
- RnM2829284 |
- 22 May, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Cardiovascular disease (CVD) is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such asischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others. These disorders are mainly reported due to obesity, high cholesterol, smoking, excessi alcohol, and poor lifestyle.
The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies.
The global Cardiovascular Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cardiovascular Drug market based on company, product type, end user and key regions.
This report studies the global market size of Cardiovascular Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cardiovascular Drug in these regions.
This research report categorizes the global Cardiovascular Drug market by top players/brands, region, type and end user. This report also studies the global Cardiovascular Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi
Market size by Product
heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Market size by End User
Hospital
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cardiovascular Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cardiovascular Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cardiovascular Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cardiovascular Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cardiovascular Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cardiovascular Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Cardiovascular Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Cardiovascular Drug Market Size Growth Rate by Product
- 1.4.2 heparin
- 1.4.3 Coumadin
- 1.4.4 Sectral
- 1.4.5 Zebeta
- 1.4.6 Lopressor
- 1.4.7 Toprol XL
- 1.4.8 Norvasc
- 1.4.9 Lotrel
- 1.5 Market by End User
- 1.5.1 Global Cardiovascular Drug Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Cardiovascular Drug Market Size
- 2.1.1 Global Cardiovascular Drug Revenue 2014-2025
- 2.1.2 Global Cardiovascular Drug Sales 2014-2025
- 2.2 Cardiovascular Drug Growth Rate by Regions
- 2.2.1 Global Cardiovascular Drug Sales by Regions
- 2.2.2 Global Cardiovascular Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Cardiovascular Drug Sales by Manufacturers
- 3.1.1 Cardiovascular Drug Sales by Manufacturers
- 3.1.2 Cardiovascular Drug Sales Market Share by Manufacturers
- 3.1.3 Global Cardiovascular Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Cardiovascular Drug Revenue by Manufacturers
- 3.2.1 Cardiovascular Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Cardiovascular Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Cardiovascular Drug Price by Manufacturers
- 3.4 Cardiovascular Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Cardiovascular Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cardiovascular Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Cardiovascular Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Cardiovascular Drug Sales by Product
- 4.2 Global Cardiovascular Drug Revenue by Product
- 4.3 Cardiovascular Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Cardiovascular Drug Breakdown Data by End User
6 North America
- 6.1 North America Cardiovascular Drug by Countries
- 6.1.1 North America Cardiovascular Drug Sales by Countries
- 6.1.2 North America Cardiovascular Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Cardiovascular Drug by Product
- 6.3 North America Cardiovascular Drug by End User
7 Europe
- 7.1 Europe Cardiovascular Drug by Countries
- 7.1.1 Europe Cardiovascular Drug Sales by Countries
- 7.1.2 Europe Cardiovascular Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cardiovascular Drug by Product
- 7.3 Europe Cardiovascular Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Cardiovascular Drug by Countries
- 8.1.1 Asia Pacific Cardiovascular Drug Sales by Countries
- 8.1.2 Asia Pacific Cardiovascular Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Cardiovascular Drug by Product
- 8.3 Asia Pacific Cardiovascular Drug by End User
9 Central & South America
- 9.1 Central & South America Cardiovascular Drug by Countries
- 9.1.1 Central & South America Cardiovascular Drug Sales by Countries
- 9.1.2 Central & South America Cardiovascular Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Cardiovascular Drug by Product
- 9.3 Central & South America Cardiovascular Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Cardiovascular Drug by Countries
- 10.1.1 Middle East and Africa Cardiovascular Drug Sales by Countries
- 10.1.2 Middle East and Africa Cardiovascular Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Cardiovascular Drug by Product
- 10.3 Middle East and Africa Cardiovascular Drug by End User
11 Company Profiles
- 11.1 Amgen
- 11.1.1 Amgen Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Amgen Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Amgen Cardiovascular Drug Products Offered
- 11.1.5 Amgen Recent Development
- 11.2 AstraZeneca
- 11.2.1 AstraZeneca Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AstraZeneca Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AstraZeneca Cardiovascular Drug Products Offered
- 11.2.5 AstraZeneca Recent Development
- 11.3 Bayer
- 11.3.1 Bayer Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Bayer Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Bayer Cardiovascular Drug Products Offered
- 11.3.5 Bayer Recent Development
- 11.4 Bristol Myers Squibb and Pfizer
- 11.4.1 Bristol Myers Squibb and Pfizer Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bristol Myers Squibb and Pfizer Cardiovascular Drug Products Offered
- 11.4.5 Bristol Myers Squibb and Pfizer Recent Development
- 11.5 Daiichi Sankyo
- 11.5.1 Daiichi Sankyo Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Daiichi Sankyo Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Daiichi Sankyo Cardiovascular Drug Products Offered
- 11.5.5 Daiichi Sankyo Recent Development
- 11.6 Johnson & Johnson
- 11.6.1 Johnson & Johnson Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Johnson & Johnson Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Johnson & Johnson Cardiovascular Drug Products Offered
- 11.6.5 Johnson & Johnson Recent Development
- 11.7 Merck & Co.
- 11.7.1 Merck & Co. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Merck & Co. Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Merck & Co. Cardiovascular Drug Products Offered
- 11.7.5 Merck & Co. Recent Development
- 11.8 Novartis
- 11.8.1 Novartis Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Novartis Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Novartis Cardiovascular Drug Products Offered
- 11.8.5 Novartis Recent Development
- 11.9 Pfizer
- 11.9.1 Pfizer Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Pfizer Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Pfizer Cardiovascular Drug Products Offered
- 11.9.5 Pfizer Recent Development
- 11.10 Portola
- 11.10.1 Portola Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Portola Cardiovascular Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Portola Cardiovascular Drug Products Offered
- 11.10.5 Portola Recent Development
- 11.11 Sanofi
12 Future Forecast
- 12.1 Cardiovascular Drug Market Forecast by Regions
- 12.1.1 Global Cardiovascular Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cardiovascular Drug Revenue Forecast by Regions 2019-2025
- 12.2 Cardiovascular Drug Market Forecast by Product
- 12.2.1 Global Cardiovascular Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Cardiovascular Drug Revenue Forecast by Product 2019-2025
- 12.3 Cardiovascular Drug Market Forecast by End User
- 12.4 North America Cardiovascular Drug Forecast
- 12.5 Europe Cardiovascular Drug Forecast
- 12.6 Asia Pacific Cardiovascular Drug Forecast
- 12.7 Central & South America Cardiovascular Drug Forecast
- 12.8 Middle East and Africa Cardiovascular Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cardiovascular Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Cardiovascular Drug . Industry analysis & Market Report on Cardiovascular Drug is a syndicated market report, published as Global Cardiovascular Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cardiovascular Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
